笔者看到chemo方案只有TP方案，立马翻到入组标准，果然Only 聚焦肺鳞癌，那么康方AK112 H6以及H3 鳞癌亚组非常具有指导意义。

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%-85% of lung cancers cases. Squamous carcinoma accounts for 20-30% of all NSCLC cases. The purpose of this study is to determine if ABBV-1480 plus chemotherapy works better than pembrolizumab plus chemotherapy in adult participants with NSCLC.

ABBV-1480 is an investigational drug being developed for the treatment of NSCLC. Participants will be randomized into 2 groups. One group will receive ABBV-1480 with platinum based chemotherapy. Another group will receive standard of care (SOC) pembrolizumab with platinum based chemotherapy. Up to approximately 940 adult participants with locally advanced (Stage IIIB/C) or metastatic (Stage IV) sqNSCLC, will be enrolled in the study in approximately 250 sites globally.

In this Phase 3 study one of two groups will receive doses of Intravenous (IV) ABBV-1480 + Carboplatin & Paclitaxel/ Nab-paclitaxel and other group will receive Intravenous (IV) Pembrolizumab + Carboplatin & Paclitaxel/ Nab-paclitaxel.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

A Randomized, Multiregional, Open-Label Phase 3 Clinical Trial of ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer

纳入标准：

Adult subjects with a histologically or cytologically confirmed diagnosis of Stage IIIB, IIIC, or IV sqNSCLC that is not amenable to curative treatment

At least one lesion with measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as determined by the local site investigator/radiology assessment.

Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions

Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

Adequate hematological, renal, hepatic, and coagulation function.

Females of childbearing potential must have a negative pregnancy test

排除标准：

Prior systemic treatment received for locally advanced or metastatic NSCLC.

Histologically or cytologically confirmed non-sqNSCLC.

Known actionable genomic alterations (including EGFR, ALK, ROS1, BRAF, NTRK, RET, and MET) for which first-line approved therapies are available. - Actionable genomic alteration testing results for EGFR and ALK are required before randomization.

Active central nervous system (CNS) metastases and/or carcinomatous meningitis.